[1]吴斯琦,丁萌譞,舒占钧.参芪地黄汤加味对脂多糖诱导人肾小管上皮细胞TLRs/NF-κB信号通路的影响[J].陕西中医,2025,46(3):320-324.[doi:DOI:10.3969/j.issn.1000-7369.2025.03.007]
　WU Siqi,DING Mengxuan,SHU Zhanjun.Effect of Shenqi Dihuang decoction on lipopolysaccharide induced TLRs/NF-κB signaling pathway in HK-2 cells[J].,2025,46(3):320-324.[doi:DOI:10.3969/j.issn.1000-7369.2025.03.007]
点击复制

参芪地黄汤加味对脂多糖诱导人肾小管上皮细胞TLRs/NF-κB信号通路的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年3期
页码:
320-324
栏目:
基础研究
出版日期:
2025-03-05

文章信息/Info

Title:
Effect of Shenqi Dihuang decoction on lipopolysaccharide induced TLRs/NF-κB signaling pathway in HK-2 cells
作者:
吴斯琦1; 丁萌譞1; 舒占钧2
(1.新疆医科大学第四临床医学院,新疆 乌鲁木齐 830099; 2.新疆医科大学第四附属医院,新疆 乌鲁木齐 830099)
Author(s):
WU Siqi1; DING Mengxuan1; SHU Zhanjun2
(1.The Forth Clinical College,Xinjiang Medical University,Urumqi 830099,China; 2.The Fourth Affiliated Hospital of Xinjiang Medical University,Urumqi 830099,China)
关键词:
慢性肾脏病;  参芪地黄汤;  脂多糖;  Toll样受体;  核因子-κB通路;  微炎症状态
Keywords:
Chronic kidney disease;  Shenqi Dihuang decoction;  Lipopolysaccharide;  Toll like receptors;  NF-κB signaling pathway;  Microinflammatory state
分类号:
R 256.5
DOI:
DOI:10.3969/j.issn.1000-7369.2025.03.007
文献标志码:
A
摘要:
目的:通过体外细胞实验研究参芪地黄汤加味对脂多糖(LPS)诱导的人肾小管上皮细胞(HK-2细胞)Toll样受体/核因子-κB(TLRs/NF-κB)信号通路的影响。方法:取雄性SD大鼠20只,随机分为对照组、给药组。对照组给予等体积0.9%氯化钠溶液灌胃; 给药组给予参芪地黄汤加味灌胃,连续给药7 d。干预后采集血液,用HK-2细胞专用培养基培养HK-2细胞。将细胞分为对照组(正常大鼠血清)、脂多糖组(正常大鼠血清与脂多糖)、参芪地黄汤低浓度组(脂多糖与5%参芪地黄汤加味含药血清)、参芪地黄汤高浓度组(脂多糖与10%参芪地黄汤加味含药血清)。各组培养24、48 h后收获细胞。酶联免疫法(ELISA)检测白介素6(IL-6)、肿瘤坏死因子α(TNF-α); 蛋白质印迹法(Western blotting)检测Toll样受体2(TLR2)、Toll样受体4(TLR4)、髓样分化因子88(MyD88)、核因子-κB(NF-κB)表达。结果:与对照组相比,脂多糖组IL-6、TNF-α水平升高,经参芪地黄汤加味干预后IL-6、TNF-α降低,差异有统计学意义(均P<0.05)。与对照组、脂多糖组相比,TLR4、MyD88、NF-κB p65降低,差异有统计学意义(均P<0.05)。结论:参芪地黄汤加味含药血清可下调炎症水平,抑制TLRs/NF-κB信号通路,改善脂多糖诱导炎症,改善CKD微炎症,保护HK-2细胞,延缓CKD进程。
Abstract:
Objective:To investigate effect of Shenqi Dihuang decoction on lipopolysaccharide(LPS)-induced Toll-like receptor/nuclear factor-κB(TLRs/NF-κB)signaling pathway in human renal tubular epithelial cells(HK-2 cells)through in vitro cell experiments.Methods:20 male SD rats were randomly divided into control group and administration group.The control group were gavaged with the same volume of 0.9% sodium chloride solution.The administration group were gavaged with Shenqi Dihuang decoction 7 consecutive days.Blood were collected after the intervention.HK-2 cells were cultured with medium dedicated to HK-2 cells.The cells were divided into control group(normal rat serum),lipopolysaccharide group(normal rat serum + lipopolysaccharide),Shenqi Dihuang low-concentration group(lipopolysaccharide + 5% Shenqi Dihuang decoction),and Shenqi Dihuang high-concentration group(lipopolysaccharide + 10% Shenqi Dihuang decoction).Cells were harvested after 24 h and 48 h of culture.The levels of interleukin 6(IL-6)and tumor necrosis factor α(TNF-α)were detected by enzyme-linked immunoassay(ELISA).Expression levels of Toll-like receptor 2(TLR2),Toll-like receptor 4(TLR4),myeloid differentiation factor 88(MyD88)and nuclear factor-κB(NF-κB)were detected by western blotting.Results:Compared with the control group,levels of IL-6 and TNF-α in the lipopolysaccharide group were significantly increased,and levels of IL-6 and TNF-α decreased after intervention of Shenqi Dihuang decoction,difference statistically significant(all P<0.05).The expression levels of TLR4,MyD88 and NF-κB p65 were significantly decreased compared with the control group and lipopolysaccharide group,difference statistically significant(all P<0.05).Conclusion:The medicated serum of Shenqi Dihuang decoction can down-regulate level of inflammation,improve inflammatory damage induced by lipopolysaccharide,improve micro-inflammatory state of CKD,protect HK-2 cells,and delay process of CKD by inhibiting the expression of TLRs/NF-κB signaling pathway.

参考文献/References:

[1] 张萌佳.三草尿毒灵治疗脾肾气虚型慢性肾脏病的临床疗效[J].中国药物经济学,2024,19(10):72-75,80.
[2] 韩娜娜,郭倩倩,程静维,等.芪蛭肾安丸治疗慢性肾脏病(气虚血瘀证)临床疗效初步探究[J].四川中医,2024,42(10):77-80.
[3] 向桃,鲁盈,钟瑜.基于数据挖掘技术探讨鲁盈治疗慢性肾脏病的用药规律[J].浙江中西医结合杂志,2024,34(9):860-863.
[4] 杨亚奇,刘云,刘岩.全身免疫炎症指数在慢性肾脏病患者中的研究进展[J].中国血液净化,2024,23(7):538-541.
[5] RAPA S F,DIIORTO B R,CAMPIGLIA P,et al.Inflammation and oxidative stress in chronic kidney disease-potential therapeutic role of minerals vitamins and plant-derived metabolites[J].Int J Mol Sci,2019,21(1):263.
[6] QIAN Q.Inflammation:A key contributor to the genesis and progression of chronic kidney disease[J].Contrib Nephrol,2017,191:72-83.
[7] NEIRYNCK N,GLORIEUX G,SCHEPERS E,et al.Soluble tumor necrosis factor receptor 1 and 2 predict outcomes in advanced chronic kidney disease:A prospective cohort study[J].PLoS ONE,2015,10:e0122073.
[8] 任克军,张磊,金华,等.清肾颗粒对非透析慢性肾脏病湿热证患者血清microRNA-21、Wnt4及β-catenin的影响[J].安徽中医药大学学报,2024,43(4):30-35.
[9] 王梦婷,蒋春波.中医药干预铁死亡治疗慢性肾脏病[J].中医学报,2024,39(9):1881-1887.
[10] 许亚威,赵紫涵,李贺,等.基于TLR2/MyD88信号通路探究五味子乙素对全身炎症反应综合征的影响[J].北华大学学报(自然科学版),2024,25(5):603-608.
[11] YUE Y,LIU X,LI Y,et al.The role of TLR4/MyD88/NF-κB pathway in periodontitis-induced liver inflammation of rats[J].Oral Dis,2021,27(4):1012-1021.
[12] 柴希,储开博,赖永健,等.小青龙汤通过TLR4/MyD88/NF-κB信号通路抑制LPS诱导慢性肾小球肾炎的机制研究[J].时珍国医国药,2023,34(10):2333-2337.
[13] 孙响波,李永伟,孙红,等.黑地黄丸对肾纤维化模型大鼠肾组织炎症因子及TLR2/NF-κB/MyD88通路的影响[J].中医杂志,2019,60(18):1593-1597.
[14] 李悦.基于NLRP3炎症信号通路探讨清肾颗粒对慢性肾衰竭患者炎症状态及LPS诱导的HK-2细胞损伤的干预机制[D].合肥:安徽中医药大学,2021.
[15] 李青青,郝建东,曹婉莹,等.利多卡因对脂多糖诱导的HK-2细胞炎症反应及TLR4/NF-κB通路的影响[J].中国实验诊断学,2024,28(9):1098-1102.
[16] KOOMAN J P,KOTANKO P,SCHOLS A M,et al.Chronic kidney disease and premature ageing[J].Nat Rev Nephrol,2014,10:732-742.
[17] CAI S,CHEN J,LI Y.Dioscin protects against diabetic nephropathy by inhibiting renal inflammation through TLR4/NF-κB pathway in mice[J].Immunobiology,2020,225(3):151941.
[18] 于冬冬,魏星宇,张晨,等.基于Toll样受体4/核转录因子-κB信号通路探讨针灸拮抗顺铂小鼠肾损伤的机制[J].中国老年学杂志,2024,44(14):3447-3453.
[19] 妮尕热?阿布都外力,王艳明,哈普拉?托留汗,等.乳源性复合益生菌对糖尿病大鼠肾组织 TLR2、TLR4 /NF-κB信号通路的影响[J].中国微生态学杂志,2020,32(11):1255-1261.
[20] 张宇,李建平,张元丽.真武汤加减联合氯沙坦钾片治疗老年早中期糖尿病肾病临床疗效及对TLR4/My D88通路的影响[J].中国老年学杂志,2022,42(7):1687-1690.
[21] 岳树香,甄云凤,霍丽梅.木丹颗粒联合西医常规治疗早期糖尿病肾病临床疗效及对患者Toll样受体4/核因子κB、转化生长因子β1/Smad信号通路的影响[J].河北中医,2020,42(5):722-726.
[22] 樊伶俐,黄益麒,沈伟钢.参芪地黄汤联合羟氯喹治疗IgA肾病的疗效观察及对Th1/Th2平衡的影响[J].中国中医药科技,2024,31(4):590-593,711.
[23] 蒋燕,朱鹏飞.参芪地黄汤联合缬沙坦对慢性肾小球肾炎患者细胞免疫和炎症反应的影响[J].陕西中医,2023,44(1):72-75.
[24] 池杨峰,刘爽,黄洁波,等.黄芪汤通过TLR4/NF-κB信号通路改善糖尿病肾病大鼠炎症反应的研究[J].临床肾脏病杂志,2022,22(1):39-45.
[25] 陈翔,丘余良.浅析黄芪在糖尿病肾脏病治疗中的作用[J].江西中医药,2024,55(11):77-80.
[26] 张淼.人参不同炮制品对脾肾阳虚大鼠的作用及机制研究[D].长春:长春中医药大学,2024.
[27] 范晓阳,侯彦婕,贾世艳,等.山药化学成分及皂苷类成分药理作用的研究进展[J].中医药信息,2021,38(9):79-84.
[28] 薄颖异.山茱萸化学成分及药理作用研究进展[J].医学信息,2024,37(16):189-192.
[29] 张树蓉,赵宏苏,佟沫儒,等.牡丹皮化学成分、药理作用及其质量标志物(Q-Marker)的预测分析[J].中草药,2022,53(16):5215-5224.
[30] 姜秋,王玲娜,刘谦,等.水蛭的炮制历史沿革、化学成分及药理作用研究进展[J].中国中药杂志,2022,47(21):5806-5816.
[31] 代琪,李康曦,叶俏波,等.僵蚕化学成分、药理作用及毒理学研究进展[J].中国药物评价,2023,40(5):402-408.
[32] 商烨,齐丽娜,金华,等.地龙化学成分及药理活性研究进展[J].药物评价研究,2022,45(5):989-996.
[33] 赵子佳,周桂荣,王玉,等.蝉蜕的化学成分及药理作用研究[J].吉林中医药,2017,37(5):491-493.
[34] 王云,张雪,麻印莲,等.熟大黄的炮制、药效及临床应用研究进展[J].中国实验方剂学杂志,2018,24(24):219-226.

相似文献/References:

[1]屈 凯,王悦彤,王漱非,等.基于文献研究探讨益肾散结法防治肾小球硬化的理论内涵*[J].陕西中医,2019,(7):919.
　QU Kai,WANG Yuetong,WANG Shufei,et al.Based on literature research to explore the theoretical connotation of Kidney-reinforcing and Mass-disintegrating for prevention and treatment of glomerulosclerosis[J].,2019,(3):919.
[2]任永朋,华 琼,刘彦妍,等.中医“治未病”思想在防治肾脏病中的应用*[J].陕西中医,2019,(8):1101.
　REN Yongpeng,HUA Qiong,LIU Yanyan,et al.The application of the thought of “preventive treatment of disease” in the prevention and treatment of kidney disease in traditional Chinese medicine[J].,2019,(3):1101.
[3]张宏强,李桂霞,章彩凤,等.许筠治疗慢性肾病临床药对举隅*[J].陕西中医,2020,(6):808.[doi:DOI:10.3969/j.issn.10007369.2020.06.031]
[4]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
　CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(3):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
[5]董 怡,马 静,余楠楠,等.大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J].陕西中医,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
　DONG Yi,MA Jing,YU Nannan,et al.Effect analysis of rhubarb compound retention enema adjuvant treatment of chronic kidney disease and its impact on patients' quality of life[J].,2021,(3):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
[6]齐 宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,(5):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
　QI Ning,SONG Shuxi,LIU Xiangyu,et al.Effects of Shenqi Yanshen recipe on the levels of Gd-IgA1,AGEs and micro inflammatory response in patients with chronic kidney disease[J].,2022,(3):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
[7]高 锐,高 珺,孙 玲,等.参芪地黄汤加减治疗肾病综合征疗效及对患者血清免疫球蛋白和补体的影响[J].陕西中医,2022,(8):1060.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.017]
　GAO Rui,GAO Jun,SUN Ling,et al.Effect of modified Shenqi Dihuang decoction on nephrotic syndrome and its effect on serum immunoglobulin and complement[J].,2022,(3):1060.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.017]
[8]麦芳雄,张香兰,朱德礼.温肾健脾清化汤辅助治疗脾肾气虚型慢性肾脏病疗效及对患者血清转化生长因子β1、纤维连接蛋白水平的影响[J].陕西中医,2022,(8):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
　MAI Fangxiong,ZHANG Xianglan,ZHU Deli.Clinical efficacy of Wenshen Jianpi Qinghua decoction in the treatment of chronic kidney disease with spleen-kidney qi deficiency and its effect on serum transforming growth factor β1 and fibronectin levels[J].,2022,(3):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
[9]杨淑彬,李 婷,李晓妮,等.不同中药结肠透析模式对慢性肾脏病患者胃肠道症状和营养状态的影响[J].陕西中医,2022,(12):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
　YANG Shubin,LI Ting,LI Xiaoni,et al.Effects of different colon dialysis modes of traditional Chinese medicine on gastrointestinal symptoms and nutritional status in patients with chronic kidney disease[J].,2022,(3):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
[10]蒋 燕,朱鹏飞.参芪地黄汤联合缬沙坦对慢性肾小球肾炎患者细胞免疫和炎症反应的影响[J].陕西中医,2023,(1):72.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.017]
　JIANG Yan,ZHU Pengfei.Effect of Shenqi Dihuang decoction combined with valsartan capsules medicine on cellular immunity and inflammatory reaction in patients with chronic glomerulonephritis[J].,2023,(3):72.[doi:DOI:10.3969/j.issn.1000-7369.2023.01.017]

备注/Memo

备注/Memo:
[基金项目]新疆维吾尔自治区重点实验室开放课题(2023D04075)
更新日期/Last Update: 2025-03-10